Innovative prostate cancer diagnostics PET/CT with Ga PSMA in Riga, LATVIA

1. http://medvision.lv/

2. Rīga Stradiņš University (RSU) is the leading institution for academic studies and
scientific research in medicine and health care in Latvia, has founded the Nuclear
Medicine Clinic to improve cancer diagnostics by PET/CT technology

3. SCIENTIFIC
CENTRE
cyclotron
radiopharmaceuticals
PRODUCTION
GMP
DIAGNOSTICS
PET/CT

4. THE ONLY NEW
GENERATION PET/CT
SCANNER IN LATVIA
OUR OWN
PRODUCTION OF
RADIOPHARMACEUTICALS
CONSTANTLY IMPROVING
EXPERIENCE IN
PERSONALIZED HEALTHCARE
SCIENTIFIC RESEARCH OF
RĪGA STRADIŅŠ UNIVERSITY IN
NUCLEAR MEDICINE

5. FDG fluorodeoxyglucose
• Breast cancer
• Melanoma
• Kidney, Bladder, Testicular cancer
• Uterine, Cervical, Ovarian cancer
• Lymphomas
• Colorectal cancer
• Lung cancer
• etc.
Ga-PSMA
• Prostate cancer
RADIOPHARMACEUTICALS

6. 68GA-PSMA?
GETTING READY FOR TOMORROW IN PROSTATE IMAGING!

7. Ga radioligand produced in generator that provides
imaging of PET with very short half life
PSMA membrane glycoprotein, part that is involved
in metabolism
Ga-PSMA PET/CT non-invasive diagnostic
technique to image prostate cancer with increased
prostate-specific membrane antigen expression
GETTING READY FOR TOMORROW IN PROSTATE IMAGING!

8. GETTING READY FOR TOMORROW IN PROSTATE IMAGING!

9. GETTING READY FOR TOMORROW IN PROSTATE IMAGING!
Physiological
Spread of
PSMA
Metastatic
Prostate
Cancer
vs

11. COMPARISON with CT and MRI
м
Diagnostic efficacy of 68Ga-PSMA PET/CT compared to
conventional imaging for lymph node staging of 130
consecutive patients with intermediate to high risk prostate
cancer
68Ga-PSMA-PET proved to be superior to standard
routine imaging in intermediate to high risk prostate
cancer preoperative lymph node staging
MAURER, Tobias, et al The Journal of urology, 2016, 195.5: 1436-1443.
м

12. COMPARISON with BS
мComparison of bone scintigraphy and 68Ga-PSMA PET/СT
for skeletal staging in prostate cancer
PSMA-PET sensitivity and specificity 98.8–99.0 % and 98.9–100 %
Bone scintigraphy sensitivity and specificity 82.4–86.6 % and 91.6–97.9 %
(p < 0.001)
PYKA, Thomas, et al. European journal of nuclear medicine and molecular imaging, 2016, 43.12: 2114-2121.
м

13. 68GA-PSMA
replaces CT of the small pelvis and abdominal
cavity, as well as MRI with better indicators of
specificity and sensitivity
GETTING READY FOR TOMORROW IN PROSTATE IMAGING!

14. PATIENT
CASE
68GA-PSMA

15. 63 y.o. male
Prostate cancer
T2aN0M0
Gleason 7 (3+4)
2013 radical prostatectomy
2015 biochemical recurrence
PSA 0,33 ng/ml  0,99 ng/ml
2015 radiation therapy for prostatic area  PSA 0,24 ng/ml
2016 rising PSA – 0,58 ng/ml
2016 PET/CT Ga-PSMA
Patient case

17. • complex examination of the whole body
• low radial load
• prostate cancer is detected even at PSA ≤ 1.0
level
• primary tumor and foci of metastasis are
visualized much more clearly than with other
diagnostic methods
• reveals the smallest metastases in the bone
• on the basis of the data obtained, an adequate
method of treatment
68GA-PSMA?
GETTING READY FOR TOMORROW IN PROSTATE IMAGING!

19. Excellent PATIENT CARE!
AFORDABLE price!
NO waiting list!
SAFE and precise!
Highly qualified medical and
technical PERSONNEL
http://rsunuclearmed.com
BEST
STANDARDS

22. WELCOME TO RSU
NUCLEAR MEDICINE CLINIC!
relatively high costs of
PET/CT lead to important
COST SAVINGS in cases of
prevention of unnecessary
surgery and other expensive
treatment of cancer
68Ga-PSMA / 1 900 €

24. CONTACTS
RSU NUCLEAR MEDICINE CLINIC
GARDENES STR.13, RIGA, LATVIA
T. +371 27-078-822
info@rsunuclearmed.com
www.rsunuclearmed.com